


# Qu-Alz: Quantum-Enhanced Early Prediction of Alzheimer's in Southeast Asia



**Full name of the speaker**

Sayed Tahlil Hossain


Universiti Teknologi Malaysia, UTM



**UTM**  
UNIVERSITI TEKNOLOGI MALAYSIA

The Qure team: Muchammad Dimas Sakti Widyatmaja, Roi Victor Roberto, Mutawally Nawwar, Sayed Tahlil Hossain

- Alzheimer's disease accounts for **60–80%** of global dementia cases.
- In Southeast Asia, prevalence rose from **29,000 (1990) → 95,000 (2021)**.
- Diagnosis often occurs **too late**, when irreversible neurodegeneration has already set in.
- Current diagnostics rely heavily on symptoms and volumetric MRI, detecting disease only after irreversible brain damage.
- Even with advances like **CNNs, ResNets, and Vision Transformers**, challenges remain:
  - Limited and imbalanced datasets
  - High computational costs
  - Low clinical interpretability and generalizability in low-resource settings



ALL SECTIONS


SEARCH


THE DIPLOMAT  
READ THE DIPLOMAT, KNOW THE ASIA-PACIFIC

ASEAN BEAT

## Is Southeast Asia Ready for a Future Dementia Epidemic?

Governments need clear plans to tackle an expected surge in dementia cases as the region ages.







# OUR METHOD- ENTANGLEMENT ENTROPY SCORE

**EES (Entanglement Entropy Score)** is a quantum-inspired metric derived from MRI slices. It quantifies how disordered or entangled a brain region appears [1][2].

$$EES = -\text{Tr}(\rho_A \log_2 \rho_A)$$

As Alzheimer's progresses, **the brain's spatial structure becomes noisier and more disorganized**, especially in critical regions like the **hippocampus**.


This increases **entanglement in the quantum state** → **higher EES**  
Thus, EES could serve as a **stage-sensitive biomarker**.

```
def compute_ees(self, mri_features: np.ndarray) -> Tuple[float, dict]:
    # Step 1: Encode features in quantum circuit
    circuit = self.create_feature_map(mri_features)

    # Step 2: Compute reduced density matrix (5:5 partition)
    rho_reduced = self.compute_reduced_density_matrix(circuit)

    # Step 3: Calculate von-Neumann entropy - this is the EES!
    ees_score = self.von_neumann_entropy(rho_reduced)
```

```
def von_neumann_entropy(self, rho: np.ndarray) -> float:
    # S = -Tr(ρ log₂ ρ) = -Σ λᵢ log₂(λᵢ)
    eigenvals = np.linalg.eigvals(rho)
    eigenvals = eigenvals[eigenvals > 1e-12] # Remove ~0 eigenvalues
    entropy = -np.sum(eigenvals * np.log2(eigenvals + 1e-12))
    return float(entropy)
```



[1] Babu, A., Ghatnekar, Saurabh G, Saxena, A., & Mandal, D. (2024). Can Entanglement-enhanced Quantum Kernels Improve Data Classification? ArXiv (Cornell University). <https://doi.org/10.48550/arxiv.2406.0194>

[2] Belanche-Muñoz, L. A., & Wiejacha, M. (2023). Analysis of Kernel Matrices via the von Neumann Entropy and Its Relation to RVM Performances. Entropy, 25(1), 154. <https://doi.org/10.3390/e25010154>

```
def predict_alzheimer_risk(image_path, category):
    # 1. Extract MRI features (64-D)
    mri_features = extractor.extract_features(image_path)

    # 2. Compute quantum EES score
    ees_score = quantum_ees.von_neumann_entropy(
        quantum_ees.compute_reduced_density_matrix(
            quantum_ees.create_feature_map(mri_features)
        )
    )

    # 3. Neural network: [MRI + EES + Category] → Risk probability
    risk_prob = model(mri_features, ees_score, category).item()

    return risk_prob # [0, 1]
```

## 🧠 ALZHEIMER'S RISK ASSESSMENT REPORT

📊 **RISK PREDICTION:**  
 Primary Assessment: 78.6% chance of Alzheimer's within 36 months  
 Uncertainty Band:  $\pm 0.2\%$   
 Risk Range: 78.4% – 78.8%

⚙️ **QUANTUM BIOMARKER:**  
 EES Score: 0.926294 bits  
 Category: Moderate Impairment

📋 **INTERPRETATION:**  
 🔴 VERY HIGH RISK – Urgent clinical assessment advised



### Phase 1 (Clinical Validation) (1–2 YEARS)

**Collaborate with neuroscience labs using datasets in South East Asia**



### Phase 2 (3–4 YEARS)

**Integrate via cloud with SEA hospitals/clinics.**



### Phase 3 (Global Collaboration) (5–6+ Years)

**Scale to LMICs and global partners.**





Developing Qu-Alz requires collaboration between quantum research, clinics, and governments.



By enabling affordable, accessible, and early-stage Alzheimer's prediction, we bridge the diagnostic gap between high- and low-resource settings in SE Asia


Targets early detection and reduces burden of Alzheimers



Qu-Alz enables cutting-edge medical technology, driving innovation in healthcare infrastructure.



**Developed Qu-Alz prototype with EES metric and hybrid LightU-Net + QCNN architecture.**





Create a regional Alzheimer's MRI dataset and designed a cloud-based platform for hospital integration.

Establish multinational research team and training programs in quantum AI for healthcare.

Produce publications on entanglement-based entropy in biomedical feature extraction.

 Parkinson's disease (PD)

 Huntington's disease (HD)



### **Targets**

Early, accurate, and accessible Alzheimer's detection in Southeast Asia using quantum-enhanced MRI analysis.

### **Method**

Integrates classical and quantum models using EES as a novel biomarker for Alzheimer's stages.

### **Scientific & Societal Impact**

Introduce quantum diagnostic tool for small datasets and standard MRI, promoting regional health equity.

### **Future Outlook**

Validate clinically, expand the framework to other neurodegenerative diseases and scale through ASEAN collaborative networks.

- Abebech Jenber Belay, Yelkal Muluaalem Walle, & Melaku Bitew Haile. (2024). Deep Ensemble learning and quantum machine learning approach for Alzheimer's disease detection. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-61452-1>
- Babu, A., Ghatnekar, Saurabh G, Saxena, A., & Mandal, D. (2024). Can Entanglement-enhanced Quantum Kernels Improve Data Classification? *ArXiv (Cornell University)*. <https://doi.org/10.48550/arxiv.2406.01948>
- Belanche-Muñoz, L. A., & Wiejacha, M. (2023). Analysis of Kernel Matrices via the von Neumann Entropy and Its Relation to RVM Performances. *Entropy*, 25(1), 154. <https://doi.org/10.3390/e25010154>
- Bomasang-Layno, E., & Bronsther, R. (2021). Diagnosis and treatment of Alzheimer's disease. *Delaware Journal of Public Health*, 7(4), 74–85. <https://doi.org/10.32481/djph.2021.09.009>
- Dementia cases set to triple by 2050 but still largely ignored. (2012, April 11). *Www.who.int*. <https://www.who.int/news/item/11-04-2012-dementia-cases-set-to-triple-by-2050-but-still-largely-ignored>
- Gopalakrishna, G., Joshi, P., Tsai, P.-H., & Patel, N. (2023). Advances in Alzheimer's Dementia: An update from Banner Alzheimer's Institute. *The American Journal of Geriatric Psychiatry*, 31(3, Supplement), S18–S19. <https://doi.org/10.1016/j.jagp.2022.12.300>
- Marcus, D. S., Fotenos, A. F., Csernansky, J. G., Morris, J. C., & Buckner, R. L. (2010). Open Access Series of Imaging Studies (OASIS): Longitudinal MRI Data in Nondemented and Demented Older Adults. *Journal of Cognitive Neuroscience*, 22(12), 2677–2684. <https://doi.org/10.1162/jocn.2009.21407>
- Modupe Odusami, Robertas Damaševičius, Egle Milieškaitė-Belousovienė, & Rytis Maskeliūnas. (2024). Alzheimer's disease stage recognition from MRI and PET imaging data using Pareto-optimal quantum dynamic optimization. *Heliyon*, 10(15), e34402–e34402. <https://doi.org/10.1016/j.heliyon.2024.e34402>